

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.

- 2013 ACC/AHA Cholesterol Guideline, 15, 17-18, 107-130
 - bottom line, 107-111
 - initiating statin therapy, 108t-109t, 111-115, 112t-114t, *116-119*, 239, 244t-245t
 - LDL-C level and statin therapy recommendations, 66, 72-75, 78-79
 - major recommendations, 108t-111t, 112t-114t
 - maximizing statin intensity, 107, 110t-111t
 - monitoring therapeutic response, 107, 115-122, *120-121*
 - move away from LDL-C and non-HDL-C treatment goals, 122, 123t
 - nonstatins in context of, 391-393, 392t
 - risk assessment, 229, 233t, 249-278, 250t-251t
 - shared decision-making, 241-245
 - statin benefit groups, 175, 177, 197, 209, 227
 - supporting evidence after 2013 release, 123-125, *124*, *126-128*
- 2013 ACC/AHA Lifestyle Guideline, 144-150
- 2013 ACC/AHA/TOS Obesity Guideline, 150-151, 152t-154t
- ACC/AHA Guidelines. See *above: entries starting with 2013*.
- Acetyl CoA, 21, 23
- Adherence to therapy, 107, 279-284. See also *Monitoring adherence*.
 - LDL-C levels as guide to, 122
 - monitoring, 109t-110t, 187, 279-284
 - regular clinic visits, 279, *280-281*
- Adolescents
 - screening for familial hyperlipidemias, 67
 - statin therapy, initiating with moderate-intensity statin, 198
- Adult Treatment Panels
 - ATP I, II, III, 16
 - ATP IV, 17, 132, 249
- Age
 - associations with total cholesterol and ASCVD risk, *50*
 - atherosclerotic plaque development and, 40, 41
 - for initiation of statin therapy, 200
- AIM-HIGH study, 56
- Alanine aminotransferase (ALT), 381-384, 382, 418t
- Alirocumab. See *PCSK-9 inhibitors*.
- ALT (alanine aminotransferase), 381-384, 382
 - ezetimibe and, 447
 - lomitapide and, 550-551
 - monitoring, 551
 - mipomersen and, 539-540
 - monitoring, 541t
 - PCSK-9 inhibitors and, 467

- Antiretroviral therapy, 100, 101t
 drug interactions with, 104-105, 305, 306t-307t
- Apolipoproteins, 55
 apo A, quantification of, 57-58
 apo AI, 32, 57-58
 apo AI-milano, 32
 apo AII, 32
 apo B, 83
 mutations, 66
 quantification of, 57-58
 atherogenicity of, 29
- ASCVD (atherosclerotic cardiovascular disease).
 See also *Cardiovascular disease*.
 clinical, 175-195, 228
 elderly individuals, statin benefit for, 177-182
 lifetime blood cholesterol, 48-49, 48, 49, 63, 65
 population subgroups (women, older adults, race/ethnicity), 285-297
 prevention, 175-195. See also *Prevention*.
 bottom line, 175-176, 209-210
 initial evaluation, 177
 lifestyle measures, 187
 nonstatins for, 107-111, 389-423, 404t-406t
 primary, in diabetic patients, 209-226
 secondary prevention (clinical ASCVD), 175-195, 338t
 statins for, 329-331, 332-337
 initiation of therapy, 176-187, 178-179
 women with, statin benefit for, 177
- ASCVD risk, 285, 299-300. See also *Prevention; Risk assessment*.
 cholesterol guidelines to reduce, 107-130, 108t-111t
 heart failure and, 300-301
 HIV infection and, 100, 304-305
 hypertriglyceridemia and, 428
 LDL-C and, 49, 50, 64, 176
 lifestyle, for risk reduction, 132-133
 lipoprotein a (Lp(a)) levels and, 58, 59
 population subgroups, 285-297
 renal disease and, 301-304
 risk assessment, 229-234, 233t, 249-278. See also *Risk assessment*.
 statin therapy and, 338t
 risk categories/classification, 252-257
 risk prediction equations, 229-232
- ASCVD risk reduction. See also *Prevention*.
 aggressive treatment in diabetics, 224
 aggressive treatment in genetic hypercholesterolemia, 202
 ezetimibe for, 443
 lifestyle measures, 132-133, 187
- ASCVD risk reduction (*continued*)
 lomitapide, 545
 nonstatins for, 107-111, 187-192, 371, 401t-402t, 404t-406t
 preferred and alternate treatments, 406t
 prevention, 175-176, 209-210
 fibrates, 507-508
 statins, 79, 131, 175-187, 183-186, 198, 329-331, 332-337, 406t, 428
- Aspirin, low-dose, 224
- Atherogenesis
 causal factors in, 38-40, 40
 cardiovascular risk factors, 37
 cholesterol, 15, 37-46, 47
 LDL-C, 37, 41
 lifestyle factors, 47-48
 total cholesterol, 37
 cholesterol and, 37-46, 47-52
 historical overview, 15-16, 27, 47
 pathophysiology, 37-40, 39, 389
 inflammation in, 38
 plaque initiation and progression, 38-40, 39, 42-45, 47
 unholy triad of, 40
 relative atherogenicity of lipoproteins, 29, 37
 thrombosis and, 38, 40, 41, 43, 45
 vascular remodeling and, 38
- Atherosclerosis
 age, and development of, 40, 41
 historical overview, 15-16, 47
 subclinical, identification of individuals with, 175
 through the lifespan, 40-41, 42-45
- Atherosclerotic cardiovascular disease (ASCVD). See *ASCVD*.
- Atherosclerotic plaque, 15, 38-40
 age, and development of, 40, 41
 cholesterol lowering and, 41
 fibrous cap, 43, 45
 initiation and progression, 38-40, 39, 42-45, 47
 rupture of, 40-41, 43, 45
- ATP. See *Adult Treatment Panels*.
- Autoimmune and inflammatory disorders, 318-320
- Bile acid sequestrants, 495-504
 action mechanism and metabolism, 496-497
 adverse effects of, 80-81, 189, 397, 419t, 500-502
 agents, 419t, 495, 499-500
 bottom line, 495
 contraindications and cautions, 83, 99, 222-223, 500
 hepatitis C, 313
 triglycerides > 300 mg/dL, 437t, 438, 495, 501

Bile acid sequestrants (*continued*)
 cost of, 495
 dosing, 499-500
 separate timing of lomitapide doses, 553
 drug-drug interactions, 502-503
 efficacy, 189, 401t, 497-498
 cardiovascular outcomes trials, 498, 499
 compared with statins, 411t
 for lipid-lowering, 411t
 indications for, 401t, 406t, 495-496
 appropriate uses, 495-496
 diabetics, ASCVD risk in, 222-223
 in familial hypercholesterolemia, 80
 LDL-C lowering, 201, 495
 safety, 500-502

Bisphosphonates, action of, 23

Blood pressure, 151-155
 control/treatment of, 132, 136, 151-155
 ACC/AHA Statement, 155, 170t, 171t
 drug treatment, 151-155, 168t-169t
 recommended drugs for CHD, 171t
 goal levels, 168t, 170t, 171t
 JNC 8 recommendations, 155, 168t-169t
 lifestyle treatment, 151, 167t
 sodium intake and, 167t
 ideal levels, 134t

Body mass index (BMI), 151, 156, 158
 ideal, 134t

Cancer, statin use and, 356, 358-360

Cancer survivors, ASCVD risk and, 321

Cardiovascular disease, epidemiology of, 47-52

Cardiovascular health, ideal, 133-137, 134t, 135, 136

Cardiovascular risk and mortality
 comparison of statins vs nonstatins, 407, 412t-415t
 familial hypercholesterolemia (FH) and, 63
 lifetime blood cholesterol and, 48-49, 48, 49, 63
 reduction with LDL-C lowering, 126, 128
 reduction with statin therapy, 175-187, 183-186, 329
 risk factors, 15-16, 37, 285

Cascade screening, 67, 69t, 82, 198, 204

Cell membrane, 21-22, 24-25, 27

Ceramides, 27

CETP (cholesteryl ester transfer protein), 28

CETP inhibitors, 28

Children
 screening for familial hyperlipidemias, 67, 204
 statin therapy, 198, 200

Cholesterol. See also *Atherogenesis*; *HDL-C*; *LDL-C*.
 atherogenesis and, 37-52, 299
 basics on, 21-26, 22-25
 as causal factor in atherogenesis, 15
 cell membrane and, 21-22, 24-25
 dietary intake, average daily, 22
 epidemiology of, 47-52
 hypercholesterolemia. See also *Familial hyperlipidemias*.
 familial (FH), 19, 63, 65-82
 polygenic, 86
 severe (LDL-C \geq 190 mg/dL), 63, 65
 laboratory measurement of, 53-61. See also *Measurement of lipoproteins*.
 non-HDL-C, 54-56, 55
 normal physiology and actions of, 21-26, 22-25
 structure of, 22
 synthesis of, 22, 23, 33
 transport of, 22-26, 33
 reverse cholesterol transport, 28

Cholesterol guideline (ACC/AHA, 2013), 17-18, 107-130

Cholesterol levels
 atherogenicity and, 47-49, 48, 49, 50
 circulating, in plasma, 47
 diet and, 16
 goal levels, 133, 134t
 LDL-C, goal levels, 16
 lifetime blood cholesterol, ASCVD and, 48-49, 48, 49, 63, 65
 total cholesterol, 134t
 ASCVD risk and, 49, 50
 in classification of hyperlipidemias, 64t
 in familial combined hyperlipidemia (FCH), 82
 in familial dysbetalipoproteinemia (Type 3), 85
 formula for, 54

Cholesterol lowering, stabilization of plaque by, 41

Cholesterol subtypes. See also *Lipoproteins*.
 HDL-C, 32, 49, 53
 LDL-C, 53, 55, 197-208

Cholesteryl ester transfer protein (CETP). See *CETP*.

Cholestyramine, 411t, 413t, 419t, 437t, 448t, 491, 495.
 See also *Bile acid sequestrants*.
 dosing, 499

Chronic kidney disease (CKD), 301-302, 303

Chylomicrons, 34-35, 55, 425
 atherogenicity of, 29
 clearance of, 33

Clinical Practice Guidelines We Can Trust, 17

Clinician-patient discussion, 241-245

- Coenzyme Q10, 379
- Colesevelam, 411t, 419t, 437t, 495, 496. See also *Bile acid sequestrants*.
 diabetics, ASCVD risk in, 222
 dosing, 500
- Colestipol, 411t, 419t, 437t. See also *Bile acid sequestrants*.
 dosing, 500
- Coronary artery calcium (CAC), 261-271, 270
- Creatine kinase (CK), 199, 282, 374
 managing elevations in, 379-381
- Cyclosporine, 303, 313, 314t-315t, 357-364
 drug interactions
 with ezetimibe, 448t
 with fibrates, 525
- CYP 3A4, 357, 361t
 inhibitors, drug interactions, 311, 313, 317, 349, 357, 364, 552
- Cytokines, 38
- Diabetes, 209-226
 high-risk patients, PCSK-9 inhibitors for, 452
 niacin, and risk of, 398, 490
 nonstatin therapy, diabetes risk with, 418t
 primary prevention in, 209-226
 ASCVD risk factors in, 211, 212t
 bottom line, 209-210
 LDL-C goal of 50% reduction, 222
 lifestyle habits, 224
 low-dose aspirin, 224
 nonstatin therapy, 222-224
 statin therapy, 80, 116, 209-222
 secondary hyperlipidemia and, 98t
 statin therapy in, 80, 116, 209-222, 338t
 diabetes risk with, 237, 282, 355, 384-385, 418t
 recommendations, 210-221, 210t, 212t-213t
 statin trials, meta-analysis of, 214-220
 type 1 (T1D), 209
 type 2 (T2D), 209, 224
 uncontrolled/untreated, hypertriglyceridemia and, 283, 428
 VLDL and, 33
- Diagnosis
 familial combined hyperlipidemia, 83
 familial hypercholesterolemia, 67-72, 70t-71t
 secondary hyperlipidemia, 99
- Diet, 131, 144-150, 431-435
 2013 ACC/AHA guidelines, 144-150, 146t, 148t
 2015 US Dietary Guideline for Americans, 132
 bottom line, 140
- Diet (*continued*)
 caloric content, 144
 cholesterol, average daily intake of, 22
 cholesterol-lowering, 16
 clinical trials on, 145-150
 ASCVD outcomes and, 145, 148, 149
 Look AHEAD, 149
 PREDIMED, 149-150
 Women's Health Initiative (WHI), 145-148
 dietary pattern, 144, 146t, 150
 dietary planning information, 148t
 diets
 DASH Eating Plan, 148t, 167t
 for lowering triglycerides, 431-433, 432t
 Mediterranean diet, 149-150, 431, 432t
 for weight loss, 152t-153t
 fat intake, 144, 148
 saturated fats, 144, 146t, 148, 431
 trans fats, 144, 146t, 431
 fatty acids in, 26-27
 impact on LDL-C, 144
 physical activity and, 145, 147t, 150
 recommendations to reduce LDL-C, 146t
 risk factors from, 26-27, 48
 sodium intake, 167t
 triglycerides, reduction with, 431-433, 432t
- Elderly individuals. See *Older adults*.
- End-stage renal disease, 302, 303-304. See also *Hemodialysis*.
- Endothelium, dysfunction of, 38, 42, 44
- Epidemiology, 47-52
- Ethnicity. See *Race/ethnicity*.
- Evolocumab. See *PCSK-9 inhibitors*.
- Ezetimibe, 386-387, 443-450
 action mechanism, 444
 added to statin therapy, 64t, 78t, 197, 201, 202, 209, 283, 413t
 clinical trials, IMPROVE-IT, 443, 444
 contraindications and cautions (pregnancy), 79, 445
 drug-drug interactions, 447, 448t
 efficacy, 444-445
 cardiovascular outcomes, 224, 390, 413t, 443, 445, 446
 LDL-C lowering, 390, 410t, 444-445
 for triglyceride-lowering, 436t, 438
 indications for, 80, 188, 201, 402t, 443
 appropriate uses, 443-444
 ASCVD reduction, 443
 based on LDL-C level, 64t, 209

- Ezetimibe, indications for (*continued*)
 - bottom line, 443
 - diabetics, ASCVD risk in, 222, 224
 - familial combined hyperlipidemia, 83, 444
 - familial hypercholesterolemia, 80, 201, 444
 - HIV patients, 305, 307t
 - homozygous sitosterolemia, 444
 - hypertriglyceridemia, 436t, 438
 - post-organ transplant, 315t, 317
 - statin-intolerant patients, 317, 378, 406t
 - safety, 445-447
 - comparison with statins, 418t
 - geriatric, 447
 - liver, 446-447
 - muscle symptoms, 446
 - pregnancy and, 445
 - renal, 447
- Familial hyperlipidemias, 63-95
 - diagnosis, apo B levels in, 58
 - familial combined hyperlipidemia (FCH), 66, 82-85
 - cholesterol/LDL-C levels in, 82
 - diagnosis, 83
 - race and, 82
 - treatment, 76, 83-85
 - ezetimibe, 83
 - monitoring therapy, 85
 - niacin, 83
 - PCSK-9 monoclonal antibodies, 83, 459-462
 - shared decision-making, 85
 - statins, 83-84
 - for triglycerides ≥ 500 mg/dL, 84-85
 - familial dysbetalipoproteinemia (Type 3), 85-86
 - treatment, 86
 - familial hypercholesterolemia (FH), 19, 63, 65-82
 - bottom line, 66
 - cardiovascular risk and mortality, 63
 - classification criteria, 70t-71t
 - diagnosis, 67-72, 70t-71t
 - genetic testing and, 82
 - incidence of, 67
 - LDL-C levels in, 65, 66, 67, 72
 - race and, 67, 75
 - screening for, 67, 68t-69t
 - treatment, 72-78, 76-77
 - goals for, 72-75, 78t
 - homozygous FH, 81
- Familial hyperlipidemias, familial hypercholesterolemia (FH), treatment (*continued*)
 - LDL apheresis, 81-82
 - lomitapide, 33, 545, 547-549, 549
 - mipomersen, 535
 - nonstatins, 80-81
 - PCSK-9 monoclonal antibodies, 80, 81, 189, 190, 399, 407, 451, 452, 459-462
 - shared decision-making, 81
 - statins, 78-80, 81
 - timing of initiation, 78
 - women/pregnancy considerations, 79, 288-289
 - women with, 79
 - familial hypertriglyceridemia, 86-88
 - polygenic hypercholesterolemia, 86
 - rare genetic lipid disorders, 88, 89t
 - screening for, 67, 68t-69t
- Family history, of hypercholesterolemia or premature ASCVD, 67-72, 73t, 82
- Family relatives, cascade screening of, 67, 69t, 82, 198, 204
- Fasting lipid panel, 177, 198
- Fasting plasma glucose, 134t
- Fat intake, dietary, 144, 148
 - saturated fats, 144, 148, 431
 - trans fats, 144, 146t, 431
- Fat-soluble vitamins, 501
- Fatigue, 320
- Fatty acids
 - classes of, 26
 - monounsaturated, 26
 - polyunsaturated, 26
 - saturated, 26
 - triglyceride transport of, 26
- Fenofibrate. See also *Fibrates*
 - contraindications and cautions, 517
 - organ transplant patients, 317
 - in pregnancy, 290
 - dosing, 509
 - drug interactions, with ezetimibe, 448t
 - efficacy
 - cardiovascular outcomes, 414t-415t, 507-508
 - in clinical ASCVD, 188
 - compared with statins, 411t, 436t
 - for lipid-lowering, 411t, 506-507
 - for triglyceride-lowering, 436t

Fenofibrate (*continued*)

indications for, 201, 401t, 406t, 508
diabetics, ASCVD risk in, 222
hypertriglyceridemia, 429, 435, 436t
secondary hyperlipidemia due to HIV, 102
metabolism, 509
safety, 201, 419t

Fenofibric acid, 411t, 419t, 436t, 509

Fibrates, 505-527. See also *Fenofibrate*; *Gemfibrozil*
action mechanism, 509, 510-511
adverse effects, 419t, 523-525
agents
 benzafibrate, 505
 fenofibrate, 505
 fenofibric acid, 505
 gemfibrozil, 505
ASCVD risk reduction with, 404t, 505-506
bottom line, 508
clinical trials, 512-517
contraindications and cautions, 84, 517
dosing, 509-512
drug-drug interactions, 448t, 525
efficacy, 512, 513t
 cardiovascular outcomes, 414t-415t, 430, 512-517, 515t, 516, 518-519
 compared with statins, 411t, 414t-415t
 for lipid-lowering, 411t, 513t
 for triglyceride-lowering, 436t, 506-507, 508
indications for, 401t, 406t, 506-508
appropriate uses, 506-508
ASCVD prevention, 507-508
based on total cholesterol *and* triglycerides, 64t, 201
based on triglyceride level, 64t, 84
clinical ASCVD, 188
familial combined hyperlipidemia, 84, 201
familial dysbetalipoproteinemia (Type 3), 86
hypertriglyceridemia, 429, 430, 435-438, 436t
pancreatitis prevention, 507
secondary hyperlipidemia due to HIV, 102
metabolism, 509
safety, 523-525

Foam cells, 38, 42-43, 44

Framingham study, 47, 229

Fredrickson classification, 63, 64t, 90t-91t

Friedewald equation, 54, 464

Gemfibrozil. See also *Fibrates*.

adverse effects, 419t
cautions and contraindications for, 517
 in combination with statins, 84, 201, 364
 drug interactions, 102, 364
 organ transplant patients, 317
dosing, 509
drug interactions, 308, 357
efficacy, 507
 cardiovascular outcomes, 414t
 compared with statins, 411t
 for lipid-lowering, 411t, 506-507
 for triglyceride-lowering, 436t
indications for, 401t, 406t, 508
metabolism, 509
safety, 419t
use in HIV patients, 102, 308

Genetic testing, 82

Genetics. See *Familial hyperlipidemias*; *Mutations*.

Glucagon, 27

Glucocorticoids, 300, 319

Glucuronidation, 357

Guidelines. See *Cholesterol guidelines*.

HDL (high-density lipoprotein), 28-32, 55
apo A-I composition of, 57-58
ASCVD risk and, 32, 49
cholesterol transport and, 28
synthesis and metabolism, 28, 30-31

HDL-C (high-density lipoprotein cholesterol), 53
ASCVD risk and, 32, 49
atherogenic levels (≥ 130 mg/dL), 49

Heart failure, 300-301
no need for risk assessment in, 115, 175, 228, 232
statin treatment and, 300-301

Hemodialysis, 115, 175, 228, 232, 249, 299
ERSD and, 302, 303-304

Hepatitis C, 310-311, 312t

High-density lipoprotein. See *HDL*.

HIV, 304-310
antiretroviral drugs, drug interactions, 104-105, 306t-307t, 308
ASCVD risk reduction, 304-310
ezetimibe, 305
PCSK-9 inhibitors, 305
secondary hyperlipidemia, 308, 309t
statins, 305
triglycerides, 308-309

HIV (*continued*)

- HAART, 100, 101t, 306t-307t
 - drug interactions, 104-105, 306t-307t, 308
 - hyperlipidemic effects of, 308, 309t
 - secondary hyperlipidemia and, 100-102
- Hydrogenation, 26
- Hypercholesterolemia, familial, 65-82, 86
- Hyperlipidemia
 - bottom line, 65
 - classification using LDL-C, triglyceride, and total cholesterol levels, 64t, 70t
 - familial, 63-95. See also *Familial hyperlipidemias*.
 - familial hypercholesterolemia (FH), 65-82
 - Fredrickson classification, 63, 64t, 90t-91t
 - secondary, 97-106, 282-283
 - bottom line, 97
 - causes of, 97-99, 98t, 282-283
 - evaluation for (to rule out), 177, 199
 - immunosuppressed patients, 102-103
 - laboratory tests for, 99
 - special populations and, 100-103
 - HIV, 100-102, 104-105, 308-309
 - organ transplant patients, 317-318
 - triglycerides and, 99
 - severe hypercholesterolemia, 63, 65
- Hypertension, 151-155
 - treatment, 151-155, 167t, 168-169t, 170t
- Hypertriglyceridemia. See also *Familial hyperlipidemias*.
 - ASCVD risk and, 428, 429
 - classification
 - 175-899 mg/dL, 425
 - mild to moderate (150-499 mg/dL), 425
 - severe (≥ 500 mg/dL), 425
 - redefinition, 425
 - 175-899 mg/dL, 425
 - ≥ 900 mg/dL, 425
 - evaluation of, 426-427
 - secondary causes, 283, 427, 428
 - familial, 86-88
 - monogenic, 87
 - mutagenic, 87-88
 - in FCH, treatment of, 84-85
 - in HIV, 308-309
 - immunosuppressed patients and, 102-103, 317-318
 - management of, 425-441
 - bottom line, 426
 - comparison of statins and nonstatins, 410t-411t

Hypertriglyceridemia, management of (*continued*)

- contraindication of bile acid sequestrants, 437t, 438, 495, 501
- diet, 431-433, 432t
- dietician referral, 431-435
- drug therapy, 427-431, 435-438, 436t
 - efficacy comparison, 436t
 - fibrates, 435-438, 436t, 506-507, 508
 - statins, 428-429
 - statins plus fenofibrate, 429
- ezetimibe, 436t, 438
- lifestyle habits, 84, 427, 429, 431-435, 432t, 531
- lomitapide, 549
- niacin, 436t, 438, 475
- omega-3 fish oils, 436t, 438, 530-531, 530
- overview, 427-428
- PCSK-9 monoclonal antibodies, 436t, 438, 462, 463
- treatment approach, 425-426
- triglyceride levels
 - < 500 mg/dL, 428-429
 - ≥ 500 mg/dL, 64t, 84-85, 426-427, 429-431
 - ≥ 1000 mg/dL, 427, 431
- monitoring therapeutic response, using non-HDL-C, 56, 59
- pancreatitis and, 427, 428, 431
 - management of, 438-439
- screening for, 425
- uncontrolled/untreated diabetes and, 283
- VLDL and, 33
- worsening by bile acid sequestrants, 222-223

IDL (intermediate-density lipoprotein), 33, 55, 425

- atherogenicity of, 29, 33, 37
- Immigrants, diet and cholesterol levels, 48
- Immunosuppressed patients, 102-103, 104-105, 299, 313-317, 314t-316t
 - cyclosporine interactions with statins, 357-364
- IMPROVE-IT, 188, 190, 202, 223-224, 292, 390, 392t, 393, 394, 443, 444
- Inflammation, 318-320
 - ASCVD risk and, 299
 - in atherogenesis, 38, 40, 42, 44-45
- Institute of Medicine, *Clinical Practice Guidelines We Can Trust*, 17
- Insulin resistance, VLDL and, 33
- Intermediate-density lipoprotein. See *IDL*.

Japanese immigrants, cholesterol levels and, 48

- JUPITER trial, 198, 211, 235, 236t, 237, 240, 291, 394

Kidney. See *Renal disease*.

Laboratory measurement. See *Measurement of lipoproteins*.

LDL (low-density lipoprotein), 34, 55

atherogenesis and, 37, 42, 44, 389

cholesterol transport by, 26

goal levels, 16

levels, direct measurement of, 56, 59

oxidation of, 37, 38, 42, 44

small, dense, 29, 34, 57

LDL apheresis, 81-82, 452

LDL-C, 53, 55

ASCVD risk and, 49, 50, 63

atherogenesis and, 37, 41, 49

lifetime exposure to very high, ASCVD and, 48-49, 48, 49, 63, 65

primary prevention (LDL-C \geq 190 mg/dL), 197-208

LDL-C levels

goal levels, 50

2013 AAC/AHA recommendations, 122-125, 123t, 124, 126-128

<50 mg/dL, 125, 126, 191, 222

50% reduction, 222, 283, 346, 393

<70 mg/dL, 125, 128, 203

with PCSK-9 monoclonal antibodies, 180, 203

70 mg/dL, 56, 78t

100 mg/dL, 75, 203

achievement with statin plus ezetimibe, 75, 78t, 396-397

in familial hypercholesterolemia, 75, 78t

LDL-C \geq 100 mg/dL, 49, 395-396

LDL-C <190 mg/dL (no diabetes), 227-248

LDL-C \geq 190 mg/dL

in classification of hyperlipidemias, 64t

in familial hypercholesterolemia, 65, 66, 67, 72

in secondary hyperlipidemia, 97

in severe hypercholesterolemia, 63, 65

treatment strategies for, 64t, 66, 338t

primary prevention, 197-208. See also *Prevention*.

LDL-C 500-1000 mg/dL, in homozygous FH, 66

measurement of

Friedewald equation, 54

non-HDL-C as surrogate, 54-56, 55

standard method: calculated LDL-C, 53-54, 59

monitoring therapeutic efficacy with, 53, 59

in newborns, 49

LDL-C lowering

ASCVD risk reduction as proportional to, 176, 329, 330, 347

comparison of statins and nonstatins, 410t-411t

lifestyle recommendations for, 144-150, 146t-147t

LDL-C lowering (*continued*)

recommended levels, 53

treatment strategies for, 64t, 197-198

contraindications to treatment, 204

ezetimibe, 390, 410t, 443-445

lomitapide, 545

mipomersen, 535, 536-537, 538

net benefit approach, 396, 403

nonstatins, 187-192, 371, 401t-402t, 404t-405t, 410t-411t

PCSK-9 inhibitors, 452, 455-457, 456

statins, 176, 180-181, 343-346, 410t

who benefits most from, 390-391

Lifestyle, 144-150. See also *Diet*.

for ASCVD risk reduction, 132-133

statin use and, 132-133, 137

benefits of healthy, 145

blood pressure control, 132, 136, 151-155

bottom line, 131-132, 136-137

cardiovascular health, 133-137, 134t, 135, 136

cholesterol levels and, 47-48

clinical trials on, 145-150

counseling on, 136, 137, 140-141, 187, 228, 234

diet, 131, 144-150

habits, 224

as predictive of ASCVD risk, 131

starting in childhood, 133, 136, 145, 228

ideal cardiovascular health, 133-137, 134t, 136

indications for

based on LDL-C level, 64t, 202

based on total cholesterol *and* triglycerides, 64t

based on triglyceride level, 64t

LDL-C lowering, aggressive changes for, 145

motivating behavior change, 137

Obesity Guideline, 150-151, 152t-154t

physical activity, 131, 133, 147t, 150, 167t

recommendations

2013 ACC/AHA Guideline, 108t, 146t-147t

diet, 144-150, 146t

physical activity, 147t, 150, 167t

in treatment of hypertriglyceridemia, 427, 429, 431-435, 432t, 531

smoking cessation, 137-144, 138t-139t, 142t-143t, 187, 224

weight loss/maintenance, 131, 132, 149, 151, 152t, 432t

Lifestyle and Risk Assessment Working Groups (NHLBI), 132, 144

Lifetime blood cholesterol, ASCVD and, 48-49, 48, 49, 63, 65

Lipid(s). See also *HDL*; *LDL*; *Lipoproteins*.

atherogenesis and, 37-46

basics on, 21-36

Lipid(s) (*continued*)

- high. See *Hyperlipidemia*.
- laboratory measurement of, 53-61
- Lipid basics, 21-36
 - HDL, 28-32, 30-31
 - metabolism, 27-28
 - normal physiology, 21-27
 - cholesterol, 21-26, 22-25
 - other lipids, 27
 - triglycerides, 26-27, 26
- Lipid-lowering goals, 16. See also *Prevention*.
- Lipid-lowering treatment. See also *Prevention*; *Statins*.
 - comparison of statins and nonstatins, 407, 410t-411t
 - goals in, 16
- Lipid-modifying drugs, historical overview, 16
- Lipoproteins, 28-35, 29. See also *HDL*; *IDL*; *LDL*; *VLDL*.
 - atherogenicity of, 29, 55
 - cholesterol transport by, 22-26
 - chylomicrons, 34-35, 55
 - HDL, 28-32
 - LDL, 34
 - metabolism of, 27-28, 30-31
 - relationship among, 55
 - transitions between, 33
 - triglycerides, 26-27
 - types, relative size, triglyceride and cholesterol composition, 29
 - VLDLs and IDLs, 33
- Lipoprotein a (Lp(a)), 34-35, 55
 - atherogenicity of, 29, 35
 - composition of, 57
 - measurement of, 58-59
 - race/ethnicity and, 58
 - risk predictive value of, 53, 59, 259, 271-272, 272-273, 274t-275t
 - treatments influencing, 35, 462, 463
- Lipoprotein lipase, 33
- Lipoprotein measurement, 53-61. See also *Measurement of lipoproteins*.
- Liver, 279
 - cholesterol synthesis in, 30-31
 - ezetimibe and, 446-447
 - function test elevations
 - comparison of statins vs nonstatins, 418t-419t
 - with lomitapide, 550-551
 - with mipomersen, 539-540, 541t
 - with niacin, 489
 - with statins, 381-384, 382, 418t
 - HDL synthesis and metabolism in, 28, 30-31

Liver (*continued*)

- hepatotoxicity (Black Box Warning)
 - lomitapide, 550-551, 552
 - mipomersen, 539, 542
- Lomitapide, 545-553
 - action mechanism, 545-546, 546
 - adverse reactions, hepatotoxicity, 33, 550-551
 - appropriate uses, 545
 - bottom line, 545
 - contraindications, 550
 - cost, 545
 - dosing, 546-547
 - dose adjustment, 547, 548t, 551
 - dose titration, 547, 547t
 - drug-drug interactions, 552-553
 - efficacy, 547-549, 549
 - indications: homozygous familial hypercholesterolemia, 33, 545
 - safety
 - hepatotoxicity, 33, 550-551
 - pregnancy, 550
 - vitamins, reduction of absorption of, 547
- Look AHEAD trial, 149, 224
- Lovastatin, 100
- Lp(a). See *Lipoprotein a (Lp(a))*.
- Macrophages, 38, 40, 42, 44
- Matrix metalloproteinases, 42, 44
- Measurement of lipoproteins, 53-61
 - apolipoprotein B and A quantification, 57-58
 - bottom line, 59
 - direct LDL, 56, 59
 - lipoprotein quantification, 56-57
 - Lp(a), 58-59
 - non-HDL-C, 54-56, 55
 - standard method: calculated LDL-C, 53-54, 59
 - triglycerides, 59
- Metabolism of lipoproteins, 27-28
- Mipomersen, 535-543
 - action mechanism, 535-536, 536
 - appropriate uses, 535
 - bottom line, 535
 - contraindications, 537
 - cost of, 535
 - dosing, 537
 - drug-drug interactions, 542
 - efficacy, 536-537, 538
 - for homozygous FH, 535

- Mipomersen (*continued*)
 indications, 535
 safety, 537-542
 hepatotoxicity (Black Box Warning), 539-540, 541t, 542
 injection site reactions, 540-542
 pregnancy, 539
- Monitoring adherence. See *Adherence to therapy*.
- Monitoring therapeutic response. See *Therapeutic response, monitoring*.
- Mortality, cardiovascular: blood cholesterol and, 48-49, 48, 49, 63, 65
- Motivation, 137
- MRFIT, 49
- Muscle
 monitoring safety with, 282
 symptoms
 in autoimmune/inflammatory diseases, 320
 with ezetimibe, 446
 with fibrates, 523
 with niacin, 490
 with nonstatin use, 418t-419t
 with PCSK-9 inhibitors, 466-467, 467
 with statin use, 354, 418t
 management of, 372t, 373-379, 376-377
- Mutagenic hypertriglyceridemia, 87-88
- Mutations, 66, 86
- Myopathy, 354, 375-378, 491
- National Cholesterol Education Program. See *NCEP*.
- NCEP (National Cholesterol Education Program)
 Adult Treatment Panels (ATP I, II, III), 16
 ATP IV, 17, 132, 249
- Netherlands Dutch Lipid Clinic Criteria, 71t, 72
- NHLBI (National Heart, Lung, and Blood Institute), 17, 132, 144, 249
- Ni-Hon-San study, 48
- Niacin, 473-493
 action mechanisms and metabolism, 475-476
 adverse effects of, 80-81, 397-398, 418t, 488-491
 bottom line, 474
 clinical trials with, 476-486, 478t, 479, 481t, 482, 483, 484-485
 combined with statins, 412t, 491
 contraindications and cautions, 488
 diabetes, 490
 in pregnancy, 79, 290, 488
 discontinue usage, 474
- Niacin (*continued*)
 dosing, 486-487
 crystalline/immediate-release (IR), 487
 extended-release (ER), 487
 reducing flushing, 487
 drug-drug interactions, 491
 efficacy, 188, 476, 477t
 ASCVD risk reduction, 404t
 cardiovascular outcomes, 412t, 476-486, 487t
 compared with statins, 410t-411t, 412t, 436t
 LDL-C lowering, 201, 410t-411t, 474
 for Lp(a) levels, 35
 for triglyceride-lowering, 436t, 438, 475
 formulations, 473-474
 indications for, 401t, 406t, 474-475
 appropriate uses, 474-475
 familial combined hyperlipidemia, 83
 familial hypercholesterolemia, 80
 hypertriglyceridemia, 436t
 safety, 488-491
 comparison of statins and other nonstatins vs, 418t
 discontinuation, 488-489
- Nicotinic acid. See *Niacin*.
- Nitric oxide synthesis, 42, 44
- Non-HDL-C, 54-56, 55, 59
 in familial combined hyperlipidemia, 82
 goal levels, 122, 123t, 126
 in monitoring therapy, 85
 statin effects on, 346, 348
- Nonstatins, 389-423. See also *specific agents*.
 added to statin therapy, 122, 188, 190-191, 197-198, 200-201, 209-210, 229, 283
 adverse events, 418t-419t
 comparison of statins vs nonstatins, 418t-419t
 discontinuance due to, 399
 agents, 389. See also *specific agents*.
 bile acid sequestrants, 495-504
 ezetimibe, 443-450
 fibrates, 505-527
 niacin, 473-493
 omega-3 fatty acids, 529-534
 PCSK-9 inhibitors (monoclonal antibodies), 451-472
 in ASCVD prevention, 107-111, 187-192, 389-423
 ASCVD risk reduction with, 187-192, 371, 404t-406t
 bottom line, 391
 choice of therapy, in high-risk patients, 400-403, 406t
 clinical trials, 389

Nonstatins (*continued*)

- ACCORD, 223
 - in cardiovascular outcomes trials, 400, 401t, 402t, 404t-405t, 412t-415t
 - HPS2-THRIVE, 188
 - IMPROVE-IT, 188, 190, 202, 223-224, 292, 390, 392t, 393, 394, 443, 444
 - compared with statins, 407-416
 - cardiovascular event reduction, 407, 412t-415t
 - lipid-lowering efficacy, 407, 410t-411t
 - safety, 407, 416, 418t-419t
 - contraindications and cautions, 290
 - efficacy
 - cardiovascular outcomes, 188-189, 223-224, 412t-415t
 - LDL-C lowering, 200-201, 209, 390-391, 400, 401t, 402t, 404-405t, 410t-411t
 - lipid-lowering, statins vs nonstatins, 407, 410t-411t
 - indications for, 109t-110t, 390-399
 - ASCVD risk in diabetes, 209, 222-224
 - based on IMPROVE-IT, 392t, 393, 394
 - based on LDL-C lowering, 200-201, 392t, 393-399
 - based on LDL-C treatment thresholds, 392t, 393-399
 - in context of 2013 ACC/HA Guideline, 391-393, 392t
 - in FH, 80-81
 - net benefit approach, 396, 403
 - older adults (age >75 years), 292
 - primary prevention (no diabetes and LDL-C \leq 190 mg/dL), 245
 - statin-intolerant patients, 317, 378, 406t
 - very high-risk patients, 399
 - in women, 290
 - lifestyle modifications in additions to, 381, 391
 - monotherapy, 189, 389, 401t-402t
 - overview, 389-390
 - patients who may benefit from, 187, 188t, 391-393
- Number-needed-to-treat (NNH/NNT), 235, 238-239, 239, 397, 398t, 403-407
- case examples for, 403, 408t-409t
 - decision-making and, 403-407
- Nursing mothers/lactation. See also *Pregnancy*.
- statins and, 204, 288-289

Obesity, 131, 150-151

- ACC/AHA/TOS Obesity Guideline, 132, 150-151, 152t-154t
- BMI and, 134t, 151, 156, 158
- bottom line, 151
- counseling about, 151, 153t
- lifestyle changes for, 131, 147t, 432t

Obesity (*continued*)

- management of (flow diagram), 156-166
 - bariatric surgery, 151, 154t
 - diets for weight loss, 152t-153t
 - recommendations, 152t-154t
 - secondary hyperlipidemia and, 98t
 - VLDL and, 33
- Older adults, 19, 290-292
 - ASCVD risk and treatment in diabetics, 221-222
 - with ASCVD, statin benefit for, 177-187, 290
 - ezetimibe safety, 447
 - mipomersen, cautions for, 542
 - nonstatin therapy, 292
 - patient preferences in therapy choices, 290-291
 - statin therapy, 291-292
- Omega-3 fatty acids, 529-534
 - action mechanisms and metabolism, 531
 - agents/formulations, 529
 - bottom line, 530
 - contraindications, 531
 - dosing, 531
 - drug-drug interactions, 532-533
 - efficacy
 - cardiovascular outcomes, 415t, 529, 530
 - compared with statins, 411t, 415t, 436t
 - for lipid-lowering, 411t
 - for triglyceride-lowering, 436t, 438, 530
 - with high-intensity statins, 84-85
 - in HIV patients, 308
 - indications for, 530
 - based on triglyceride level, 64t, 432t, 433, 438, 530
 - familial combined hyperlipidemia, 84-85
 - familial dysbetalipoproteinemia (Type 3), 86
 - organ transplant patients, 317
 - pancreatitis prevention, 530
 - secondary hyperlipidemia due to HIV, 102
 - marine sources for, 411t, 432t, 434t, 529
 - safety, 419t, 532
- Pancreatitis, 427, 428, 431
 - management of, 438-439
 - prevention of, 507
- Patient
 - clinician-patient discussion, 241-245
 - patient preferences, 187, 191, 203-204, 221, 241-245, 290-291
 - shared decision-making, 81, 85, 228, 241-245

PCSK-9 inhibitors (monoclonal antibodies), 20, 399, 451-472
about PCSK-9
 discovery, 452-453
 full name, 451
 PCSK-9 monoclonal antibodies, 455-457
 PCSK-9 mutations, 66, 452-453
action mechanism, 453-457, 454
added to statin therapy, 191
 do not downtitrate the statin dosage, 452
adverse reactions, 465-469
agents (PCSK-9 mAbs), 451, 455-457
 alirocumab, 189, 223, 410t, 436t
 dosing, 464
 LDL-C lowering, 457, 458
 evolocumab, 189, 223, 410t
 dosing, 464
 LDL-C lowering, 458-459, 458, 460-461
 vs ezetimibe, 459
 FDA-approved in the U.S., 451, 452
 pharmacodynamics, 455-457, 456
bottom line, 451-452
contraindications and cautions, 465
 HIV, 305
 pregnancy, 79, 204, 290, 465-466
cost of, 203, 451
dosing, 464-465
 low LDL-C levels and, 464-465
drug-drug interactions, 469
efficacy
 ASCVD risk reduction, 405t, 463-464
 cardiovascular outcome trials are ONGOING, 451, 452, 463-464
 compared with statins, 410t, 436t
 effects on other lipids and lipoproteins, 462, 463
 increased by concurrent statin use, 453-455, 454, 469
 LDL-C lowering, 78, 190, 201, 223, 410t, 452, 455-457, 456, 457-462
 for Lp(a) levels, 35, 462, 463
 subgroup efficacy, 459
 for triglyceride-lowering, 436t, 438
FDA-approved uses, 189, 451-452
indications for
 appropriate uses, 452
 based on LDL-C level, 64t, 80, 399, 451-452
 based on total cholesterol *and* triglycerides, 64t
 bottom line, 451-452
 clinical ASCVD, 189, 451
 diabetics, ASCVD risk in, 223

PCSK-9 inhibitors (monoclonal antibodies), indications for
 (*continued*)
 familial combined hyperlipidemia, 83
 familial hypercholesterolemia (FH), 80, 81, 189, 190, 399, 407, 451, 452, 459-462
 hypertriglyceridemia, 436t, 438
 LDL-C lowering in FH or clinical ASCVD, 451
 maximizing statin therapy, 451
 statin-intolerant patients, 317, 378, 406t, 459
 low LDL-C levels and, 464-465, 468-469
 safety, 465-469
 tolerability of, 371
Periodontal disease, 319
Physical activity, 131, 133, 144
 recommendations for, 134t, 145, 147t, 150, 167t
 brisk walking, 145
 vigorous vs moderate, 145
Physical inactivity, 131
Plaque. See *Atherosclerotic plaque*.
Population subgroups. See *Special populations*.
PREDIMED trial, 149-150
Pregnancy
 contraindications and cautions
 bile acid sequestrants, 500-501
 ezetimibe, 79, 445
 fibrates, 523
 lomitapide, 550
 niacin, 79, 290, 488
 nonstatins, 290
 PCSK-9 inhibitors (mAbs), 79, 204, 290, 465-466
 statins, 79, 204, 288-289, 349, 354
 mipomersen use in, 539
 treatment issues in familial hypercholesterolemia (FH), 79
Prevention
 cost-benefit analysis, 239
 primary prevention
 older adults (age >75 years), 291-292
 risk assessment for, 19, 227-228, 249-278
 statins for, 330-331, 338t-339t
 primary prevention (diabetes), 209-226
 bottom line, 209-210
 lifestyle habits, 224
 nonstatin therapy, 222-224
 persons <40 years, 221
 persons >75 years, 221-222
 statin therapy, 108t, 209-222
 recommendations, 210t, 212t-213t
 statin trials, meta-analysis, 214-220

Prevention (*continued*)

- primary prevention (LDL-C \geq 190 mg/dL), 197-208
 - adding nonstatin therapy, 200-201
 - bottom line, 197-198
 - contraindications to treatment, 204
 - duration of therapy, 203
 - genetic lipid disorders and, 197
 - initiating statin therapy, 198-200
 - lifestyle factors, 202
 - treatment thresholds, 202-204
- primary prevention (no diabetes and LDL-C \leq 190 mg/dL), 227-248
 - bottom line, 228-229
 - clinician-patient discussion, 241-245
 - nonstatin therapy, 245
 - risk assessment and treatment algorithm, 227-228, 230-231
 - statin therapy, 228-229, 235-239
- secondary prevention (clinical ASCVD), 175-195
 - bottom line, 175-176
 - lifestyle measures, 187
 - monitoring therapy and adherence, 187
 - nonstatins for, 107-111, 187-192, 389-423
 - nonstatins in, 389-423
 - older adults (age $>$ 75 years), 291
 - PCSK-9 inhibitors, 451, 452
 - statins for, 175-187, 338t
- Proteinuria, 98t

Race/ethnicity, 292-293

- ASCVD risk and, 285
- East Asians, 293
- familial combined hyperlipidemia and, 82
- familial hypercholesterolemia and, 67, 75
- lifestyle factors and, 47-48
- lipoprotein a (Lp(a)) and, 58
- risk assessment, 252, 270, 292-293
- special issues in treatment, 19
- statin therapy, 293

Red yeast rice, 379

Renal disease, 301-304, 349

- chronic kidney disease (CKD), 301-302, 303
- ESRD/hemodialysis, 302
- renal transplant, 303, 304

Renal function

- fibrate dose adjustment and, 509-512
- fibrates and, 524
- statins and, 349

Reverse cholesterol transport, 28

Risk assessment, 19, 175, 249-278

- ACC/AHA cholesterol guidelines (2013), 229, 233t, 249-278, 250t-251t
 - ACC/AHA risk calculator, 227-228, 230-231, 249
 - additional factors in, 234, 234t
 - bottom line, 249-252
 - calibration, 259, 264-265
 - categories/classification
 - 10-year ASCVD risk, 253-256, 255t
 - lifetime risk, 252
 - reclassification, 260, 266-269
 - discrimination in, 257-259, 258t
 - guideline for whether to assess risk or not, 232, 233t
 - lifetime risk, 252
 - lower-risk patients, benefits of treating, 237-239, 242-243
 - not necessary for patients with heart failure and hemodialysis, 115, 175, 228, 232, 249
 - primary prevention (LDL-C $<$ 190 mg/dL), 227, 249-278
 - primary prevention (no diabetes and LDL-C $<$ 190 mg/dL), 227-228
 - race and, 252, 270
 - race/ethnicity and, 292-293
 - risk indicators, 254-256, 255t
 - coronary artery calcium (CAC), 261-271, 270
 - lipoprotein a (Lp(a)), 259, 271-272, 272-273, 274t-275t
 - new biomarkers, 256-257, 257t, 260, 262-263
 - risk prediction calculator, 232
 - risk prediction equations, 229-232
 - Pooled Cohort Equations, 253-254, 258t, 261, 292
 - for statin therapy, 228-234, 233t, 338t
 - summary of recommendations, 250t-251t
- Risk factors
- cardiovascular, 15-16
 - control of, 234-235
 - dietary, 26-27, 48
- Safety, 279-282, 539. See also *specific agents*.
- comparative data for statins vs nonstatins, 407, 416, 418t-419t
- Screening
- cascade screening, 67, 69t, 82, 198, 204
 - for familial hyperlipidemias, 67, 68t-69t, 425
 - for hypertriglyceridemia, 425
- Secondary hyperlipidemia, 97-106. See also *Hyperlipidemia, secondary*.
- Secondary prevention. See *Prevention*.
- Shared decision-making, 81, 85, 228, 241-245
- Simvastatin, 100
- Sitosterolemia, 444

Smoking, 133, 134t, 137-144
 bottom line, 141-144
 cessation of, 137-144, 138t-139t, 187, 224
 pharmacotherapy for, 141, 142t-143t
 diabetes and, 224

Special populations and subgroups, 285-293, 299-328
 autoimmune and inflammatory disorders, 318-320
 cancer survivors, 321
 heart failure, 300-301
 hepatitis C, 310-311, 312t
 HIV, 304-310
 older adults (age >75 years), 290-292
 race and ethnicity, 292-293
 renal disease, 301-304
 women, 285-290

Sphingosine and sphingomyelin, 27

SREBP 1 and 2 (sterol regulatory binding proteins), 21, 453

Statins, 329-368. See also *Nonstatins*.
 action mechanism, 21, 23, 331-343
 pleiotropic effects, 343, 344-345
 adverse effects, 354-356, 369-388, 418t-419t
 blood glucose elevation, 384-385
 bottom line, 369-371
 cancer, 356, 358-360
 cognitive function, 355-356
 comparison of statins vs nonstatins, 418t-419t
 creatine kinase elevation, 379-381
 diabetes, 237, 282, 288, 355, 384-385, 419t
 dosage/intensity and, 369-371
 genetics and, 373
 hemorrhagic stroke, 354-355
 hepatic transaminase elevation, 354
 liver function test elevations, 381-384, 382, 418t
 management of, 329-368
 mood, 356
 muscle symptoms, 354, 418t
 management of, 372t, 373-379, 376-377
 neuropathy, 356
 nonstatins as alternatives, 378
 number-needed-to-treat (NNH/NTT), 235, 238-239, 239, 397, 398t
 predisposing factors for, 369, 370t-371t, 371, 373
 sex and, 288
 supplemental vitamins for, 379
 agents, 312t, 314t-316t, 331, 340t-341t
 drug interactions of, 362t-363t
 pharmacokinetics of, 361t
 structural formulas for, 342-343

Statins (*continued*)
 ASCVD risk reduction with, 79, 131, 132-133, 137, 175-187, 183, 183-186, 198, 329-331, 332-337, 428
 benefit groups for, 175, 177, 197, 209, 227, 310
 bottom line, 364
 clinical trials, 111-115, 112t-114t, 177, 198, 235, 236t, 344-345
 AFCAPS/TexCAPS, 235, 236t, 240
 exclusion criteria for, 347, 350t-353t
 JUPITER, 198, 211, 235, 236t, 237, 240, 291, 394
 MEGA22-24, 235, 236t, 240
 meta-analysis of, 214-220
 older adults, 291-292
 PROVE-IT, 177, 198, 202
 TNT and IDEAL, 75, 177, 198, 202
 women and, 290

combined with
 ezetimibe, 64t, 78t, 190-191, 283
 for clinical ASCVD, 176, 182
 for LDL-C lowering, 197
 nonstatins, 122, 176, 190-191, 197-199, 229, 283
 cardiovascular outcomes, 412t-415t
 for LDL-C lowering, 200-203
 PCSK-9 inhibitors (monoclonal antibodies), 191

compared with nonstatins, 407-416
 cardiovascular event reduction, 407, 412t-415t
 lipid-lowering efficacy, 407, 410t-411t
 safety, 407, 416, 418t-419t
 for triglyceride-lowering, 436t

contraindications and cautions, 349-354
 hepatitis C, 311, 312t
 immunosuppressed patients, 313-317, 314t-316t
 lack of benefit for heart failure and hemodialysis patients, 115, 175, 228, 299
 in pregnancy, 79, 204, 288-289, 349, 354
 renal function, 349
 use with gemfibrozil, 84, 201, 364

development of, 16
 diabetes risk of statin use, 237, 282, 384-385
 in diabetics (statin use in), 80, 209-222, 338t
 drug-drug interactions, 356-364, 362t-363t
 cyclosporine, 357-364
 with fibrates, 357, 364
 with HIV treatments, 305, 306t-307t
 metabolized by CYP 3A4, 357, 361t
 not metabolized by CYP 3A4, 357, 364

Statins (*continued*)

efficacy

cardiovascular event reduction, 412t-415t
effects on other lipids, 346-347, 348
LDL-C lowering, 176, 180-181, 182, 343-346
lipid-lowering, statins vs nonstatins, 407, 410t-411t
pleiotropic effects, 343, 344-345
high-intensity, 116, 199, 331, 338t
adverse events, 418t
agents, 340t-341t
atorvastatin, 115, 175, 199, 340t
rosuvastatin, 115, 175, 199, 211, 291, 340t
for clinical ASCVD, 177-182, 178, 182
combined with nonstatins, 201
combined with omega-3 fatty acids, 84-85
for diabetics, 209, 211, 221-222
duration of therapy, 222
for familial combined hyperlipidemia, 83, 84-85
for familial dysbetalipoproteinemia (Type 3), 86
for familial hypercholesterolemia, 75, 76
indications for, 331, 340t-341t
initiating therapy with, 178, 197, 228, 229
LDL-C <190 mg/dL (no diabetes), 235
LDL-C \geq 190 mg/dL, 198, 199, 199t
LDL-C reduction levels, 53, 75, 198
indications for, 112t-114t, 329-331
based on LDL-C level, 64t, 66, 76, 79, 83, 198-199, 199t
based on total cholesterol *and* triglycerides, 64t
based on triglyceride level, 64t
in children, 200
clinical ASCVD (secondary prevention), 175-187
diabetes, ASCVD prevention in, 116, 209-226
familial combined hyperlipidemia, 83-84
familial hypercholesterolemia, 75, 76, 78-79, 78t, 81, 204
heart failure, patients with, 300-301
hypertriglyceridemia, 428-429
immunosuppressed patients, 102, 104, 313-317, 314t-316t
in older adults, 291
primary prevention of ASCVD, 330-331, 338t-339t
race/ethnicity and, 293
secondary hyperlipidemia due to HIV, 100
in special clinical populations, 299-328
statin intensity, 331, 338t-341t
initiation of therapy, 338t
2013 ACC/AHA Cholesterol Guideline, 108t-109t, 111-115, 112t-114t, 116-119, 239, 244t-245t
for clinical ASCVD, 176-187, 178-179, 182, 338t

Statins, initiation of therapy (*continued*)

initial evaluation, 198-199
LDL-C \geq 190 mg/dL, 198-200, 338t
for primary prevention (no diabetes and LDL-C \leq 190 mg/dL), 228-229, 235-239
risk assessment for, 227-228, 228-229, 230-231
women, 288
low-intensity, agents, 340t-341t
metabolism of, 349
moderate-intensity
adverse events, 418t
agents, 340t-341t
for ASCVD prevention in diabetic patients, 210-211
for clinical ASCVD, 175, 182-187, 182
for diabetics, 211, 221, 338t
ezetimibe added to, 190-191
for FH, 200
guideline for, 116-119
initiating therapy with, 178, 198, 200, 228, 229
LDL-C <190 mg/dL (no diabetes), 235
monitoring therapeutic response, 115-122, 120-121
anticipated responses, 115
indicators of adequate therapy, 76
patient selection, 347-349, 350t-353t
recommendations for, 18, 111-122
2013 ACC/AHA Cholesterol Guideline, 108t-109t, 111-122, 112t-114t
appropriate intensity of statin therapy, 108t-109t
maximizing statin intensity, 107, 110t-111t
ASCVD prevention in diabetics, 210t, 212t-213t
in clinical ASCVD, 175-187, 182
as first-line therapy, 16, 18, 176, 329
older adults (> 75 yrs), 177-187
risk assessment for, 227-234, 233t, 338t
safety data, 407, 416, 418t-419t
safety monitoring, 279-282
statin intensity, 338t-341t
choice for women, 289
high-intensity. See *Subentry above for high-intensity*.
maximizing/maximally tolerated, 107, 110t-111t, 175, 199, 221, 283, 284, 331, 426
moderate- and high-intensity, guideline for, 116-119, 338t-341t
tolerability of, 369-379
partial or complete intolerance, 378, 406t
Steroid hormones, cholesterol and, 21
Stroke, statin use and, 354-355

- Tendon xanthoma, 72, 74
- Therapeutic response
 evaluating, 282-283
 anticipated response, 282
 secondary causes of hyperlipidemia, 282-283
 monitoring, 187, 279-284
 2013 ACC/AHA Cholesterol Guideline, 107, 109t-110t, 115-122, 120-121
 regular clinic visits (follow-up), 279, 280-281
 safety, evaluating, 279-282
 statin therapy, 115-122, 120-121
 using LDL-C, 53, 59, 282
 using non-HDL-C, 56, 85
 treatment intensification, 283
- Thrombosis, 38, 40, 41, 43, 45, 299
 occlusive vs nonocclusive, 41
- Tolerability, monitoring, 279-284
- Total cholesterol. See *Cholesterol levels*.
- Trans fats. See *Fat intake*.
- Transplantation (organ transplants), 311-318
 ASCVD risk after, 311-313
 immunosuppressed patients, 102-103, 104-105
 ezetimibe, 315t, 317
 statins and, 313-317, 314t-316t
 renal transplant, 303, 304
 secondary hyperlipidemia, management of, 317-318
- Treatment. See also *specific agents and classes of agent*.
 ACC/AHA Cholesterol Guideline (2013), 17-18, 107-130, 108t-111t
 bile acid sequestrants, 495-504
 duration of therapy, 203
 ezetimibe, 443-450
 familial combined hyperlipidemia, 76, 83-85
 familial dysbetalipoproteinemia (Type 3), 86
 familial hypercholesterolemia, 72-82, 76, 78t
 fibrates, 505-527
 for hypertriglyceridemia, 425-441
 intensification of, 283
 lifestyle recommendations, 19, 144-150
 lipid-lowering goals, 16
 lomitapide, 545-553
 mipomersen, 535-543
 monitoring therapeutic response, adherence, and tolerability, 279-284
 niacin, 473-493
 nonstatins, 18, 80-81, 107-111, 389-423
 omega-3 fatty acids, 529-534
- Treatment (*continued*)
 PCSK-9 inhibitors (monoclonal antibodies), 451-472
 population subgroups (women, older adults, race/ethnicity), 285-297
 safety, 279-282. See also *specific agents*.
 statins vs nonstatins, 407, 416, 418t-419t
 shared decision-making, 81, 85, 228, 241-245
 special populations, 19, 285-293, 299-328
 statins, 329-388
 strategies based on LDL-C, triglyceride, and total cholesterol levels, 64t
- Triglycerides, 26-27. See also *Hypertriglyceridemia*.
 ASCVD risk and, 428
 levels
 150-400 mg/dL, 59, 425
 in secondary hyperlipidemia, 97
 400-500 mg/dL, 59, 428-429
 ≥500 mg/dL, 59, 63, 425
 in classification of hyperlipidemias, 64t
 in familial combined hyperlipidemia, 84-85
 in familial dysbetalipoproteinemia (Type 3), 85
 in familial hypertriglyceridemia, 86-87
 in secondary hyperlipidemia, 99
 treatment strategies for, 64t, 84-85, 429-431
 ≥1000 mg/dL, 84, 427
 measurement of, 59
 non-HDL-C, 54-56, 55, 59
 recommended, 59
 redefinition of states, 425
 175-899 mg/dL, 425
 ≥900 mg/dL, 425
 normal physiology of, 26-27
 statins, lowering of triglycerides by, 346
 storage of, 27
 structure of, 26, 26
- Vascular remodeling, 38, 43, 45
- Very low-density lipoprotein. See *VLDL*
- Vitamins
 fat-soluble, 501
 reduction of absorption, by lomitapide, 547, 553
 vitamin D, 379
- VLDL (very low-density lipoprotein), 33, 55, 425
 atherogenicity of, 29, 33, 37
 in familial combined hyperlipidemia, 83, 85
 in familial dysbetalipoproteinemia (Type 3), 85
 VLDL-C, 53

Weight loss, 131, 132, 149, 151, 432t. See also *Diet*.

diets for, 152t-153t

Women, 285-290

with ASCVD, risk reduction with LDL-C lowering, 285, 286-287

atherosclerotic development in, 40

nonstatin therapy, 290

risk assessment, CAC and, 263

special issues in treatment, 19

 familial hypercholesterolemia (FH), 79

 statin therapy, 288-289

 ASCVD risk reduction with, 177, 285-288

Women's Health Initiative (WHI), 145-148

Xanthoma, xanthelasma, 72, 74

Zetia. See *Ezetimibe*.